Figure 2.
Genetic mutation landscape and drug sensitivity analysis of immune checkpoints in KIRC. (A) Oncoplot displaying genetic mutation landscape of immune checkpoints in TCGA KIRC cohort. (B) The activation and inhibition of immune checkpoints in KIRC-related pathways. (C) The correlation between immune checkpoints and drug or small molecules. The positive correlation means that the gene high expression is resistant to the drug, vise verse. (D) A heat map of the correlation between each member of immune checkpoints.
